EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer.
about
Targeting the Eph System with Peptides and Peptide ConjugatesExpression of EphA2 protein is positively associated with age, tumor size and Fuhrman nuclear grade in clear cell renal cell carcinomasNovel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma.Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer.Inhalable oridonin-loaded poly(lactic-co-glycolic)acid large porous microparticles for in situ treatment of primary non-small cell lung cancer.Lung cancer nanomedicine: potentials and pitfalls.Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer.Evaluation of Spray BIO-Max DIM-P in Dogs for Oral Bioavailability and in Nu/nu Mice Bearing Orthotopic/Metastatic Lung Tumor Models for Anticancer Activity.Lipid-based oral delivery systems for skin deposition of a potential chemopreventive DIM derivative: characterization and evaluation.Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer.Treatment of Dutch rat models of glioma using EphrinA1-PE38/GM-CSF chitosan nanoparticles by in situ activation of dendritic cells.Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.
P2860
Q26799461-2BFA0826-4177-4C8B-AE92-E428A0574E1FQ36375472-F20E9FA9-BB36-4B53-9E72-8C00CE53BCEBQ36641553-C058B102-33CA-46A6-BDCF-9194101F2F1AQ37013337-296FF479-442A-4B2E-A0DE-8368F8B84448Q37587394-A81C8B11-7E0A-438C-BFF4-EB51B64E4D22Q38608622-C7910CF5-D96D-4844-BD48-B6B96A7E125EQ38778869-7DCD24CA-B7AF-465C-9428-DB280F328D94Q38921461-BE2F2D97-022D-4142-B756-BFAEE11AD02EQ39609219-AA7F469B-7B90-4763-8BE6-214483A8EDE8Q46058008-3340F724-65E7-4939-B0DD-4BBFD5795972Q48186040-43608C5C-05B3-43B9-B732-15A99D6F6EFDQ51749008-47431BF1-D6B8-4DC7-BB22-1E3109248172
P2860
EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer.
@en
type
label
EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer.
@en
prefLabel
EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer.
@en
P2093
P2860
P1476
EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer.
@en
P2093
Apurva R Patel
Mahavir Chougule
Mandip Singh
P2860
P304
P356
10.1007/S11095-014-1377-4
P577
2014-05-29T00:00:00Z